Tag: firstline
Watch out, Merck: FDA grants Regeneron, Sanofi’s Libtayo priority review for...
One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung...